New pharma products integral to Merck KGaA's growth prospects

10 September 2021
merck_kgaa_new_large

Life sciences major Merck KGaA (MRK: DE) has outlined its strategy for ensuring accelerated growth during a Capital Markets Day on Thursday.

The German company is aiming for group sales of around 25 billion euros ($30 billion) in 2025, where in 2020 this figure was 17.53 billion euros.

Merck expects a major part of this growth to come from the Healthcare division, where medium-term average annual organic sales growth in the mid single-digit percentage range is predicted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology